Stereotactic body radiotherapy for extracranial oligometastatic breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter retrospective database collects clinical and treatment data from adults with extracranial oligometastatic or oligoprogressive breast cancer who received SBRT at participating Italian centers. Included cases must have histologically confirmed breast cancer and SBRT delivered at a minimum equivalent dose of 50 Gy EQD2 in no more than 12 fractions. Investigators will analyze outcomes such as local control, progression-free survival, overall survival, and treatment-related toxicity across institutions. The project aims to clarify whether SBRT provides consistent disease control or survival advantages given prior heterogeneous results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients ≥18 years
* Histological diagnosis of breast cancer
* Oligometastatic or oligoprogressive metastatic breast cancer
* SBRT delivered to a minimum dose of 50Gy EQD2 (αβ 10 Gy),in a maximum of 12 fractions as per Oligocare definition
* Ability to provide written informed consent

Where it's running

• Humanitas Gavazzeni
  Bergamo, Bergamo, Italy Recruiting
• Spedali Civili
  Brescia, Bs, Italy Recruiting
• Responsible Research Hospital
  Campobasso, Cb, Italy Recruiting
• Fondazione I.R.C.C.S Istituto Nazionale Tumori di Milano
  Milan, Milano, Italy Recruiting
• IRCCS Humanitas Research Humanitas
  Rozzano, Milano, Italy Recruiting
• INT IRCCS Fondazione G. Pascale
  Naples, Napoli, Italy Recruiting

Study contacts

• Study coordinator: Ruggero Spoto, MD, Radiation oncologist
• Email: ruggero.spoto@cancercenter.humanitas.it
• Phone: +39 0282248508

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for Oligometastatic Breast Cancer

  This study is testing if adding a special treatment for metastatic breast cancer, like surgery or targeted radiation, can help patients do better after starting their regular cancer therapy.

  Recruiting Phase 3 Tokyo Medical and Dental University · Bunkyō-Ku, Tokyo · NCT06135714

• Testing a new type of radiotherapy using an MR-Linac device

  This study tests a new type of radiotherapy using a special machine that combines imaging and treatment to see if it can better target tumors while protecting healthy tissue.

  Recruiting University Hospital Tuebingen · Tübingen, Baden-Wurttemberg · NCT04172753

• Comparing radical and palliative treatments for breast cancer with specific bone metastases

  This study is testing whether aggressive treatment for breast cancer with specific bone metastases can help patients feel better and live longer compared to just focusing on pain relief.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 3 other locations · NCT04158843

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.